Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies

All companies

174 clinical-stage companies. Search or filter to narrow the list.

Ticker Company Therapeutic areas Lead stage Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare Phase 3 5
ABSI Absci DermatologyGI/Hepatology+1 Phase 1 7
ACIU AC Immune Neurology Rare Phase 3 11
ACRS Aclaris Therapeutics DermatologyRespiratory Phase 2 7
ACRV Acrivon Therapeutics Oncology Phase 2 5
ACTU Actuate Therapeutics Oncology Phase 2 8
ABOS Acumen Pharmaceuticals Neurology Phase 2 4
ADAG Adagene Oncology Phase 2 9
ADCT ADC Therapeutics Oncology Approved 5
ADMA Adma Biologics Infectious Disease Approved 4
AGMB Agomab Therapeutics ImmunologyRespiratory Rare Phase 2 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare Approved 10
AKTS Aktis Oncology Oncology Phase 1 9
ALDX Aldeyra Therapeutics DermatologyOncology+1 Rare NDA Submitted 8
ALLO Allogene Therapeutics ImmunologyOncology Rare Phase 2 12
DRTS Alpha Tau Medical Oncology Phase 2 5
ATHE Alterity Therapeutics Neurology Rare Phase 3 2
ALT Altimmune GI/HepatologyMetabolic+1 Phase 2 3
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare Phase 3 5
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare Approved 6
ANNX Annexon HematologyNeurology+2 Rare NDA Submitted 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare Phase 2 9
APVO Aptevo Therapeutics Oncology Phase 1 8
RCUS Arcus Biosciences DermatologyImmunology+1 Phase 3 6
ARDX Ardelyx Renal Approved 4
ARTV Artiva Biotherapeutics DermatologyImmunology+2 Rare Phase 2 16
ARVN Arvinas NeurologyOncology Rare Approved 15
ATAI Atai Beckley Neurology Phase 3 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare Approved 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare Phase 1 7
BCAX Bicara Therapeutics Oncology Phase 3 4
BIOA BioAge Labs CardiovascularOphthalmology Phase 1 2
BMEA Biomea Fusion Metabolic Phase 2 5
BCTX BriaCell Therapeutics Oncology Phase 3 8
BBOT BridgeBio Oncology Therapeutics Oncology Phase 1 8
CCCC C4 Therapeutics Oncology Phase 2 2
CABA Cabaletta Bio DermatologyImmunology+2 Rare Phase 1 8
CAPR Capricor Therapeutics Neurology Rare NDA Submitted 1
CRDL Cardiol Therapeutics Cardiovascular Rare Phase 3 4
CRBU Caribou Biosciences Oncology Phase 3 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare Phase 3 4
CLDX Celldex Therapeutics DermatologyImmunology+1 Phase 3 7
CLRB Cellectar Biosciences Oncology NDA Submitted 11
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare Phase 1 11
CRVO CervoMed Neurology Rare Phase 3 5
CGON CG Oncology Oncology NDA Submitted 1
CING Cingulate Neurology NDA Submitted 1
CLNN Clene Neurology Rare NDA Submitted 5
CLYM Climb Bio HematologyImmunology+1 Rare Phase 2 7
COGT Cogent Biosciences HematologyOncology Rare NDA Submitted 6
CGTX Cognition Therapeutics Neurology Phase 2 2
CHRS Coherus Oncology Oncology Approved 4
CMPS COMPASS Pathways Neurology NDA Submitted 3
CGEN Compugen Oncology Phase 3 7
CNTB Connect Biopharma Respiratory Phase 2 4
CRVS Corvus Pharmaceuticals DermatologyOncology Phase 3 4
CBIO Crescent Biopharma Oncology Phase 1 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare Approved 6
CUE Cue Biopharma Oncology Phase 1 4
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare NDA Submitted 10
HELP Cybin Neurology Phase 3 3
CYDY CytoDyn NeurologyOncology Phase 2 3
CTMX CytomX Therapeutics Oncology Phase 1 3
DBVT DBV Technologies GI/HepatologyImmunology Rare NDA Submitted 3
DFTX Definium Therapeutics Neurology Phase 3 4
DYN Dyne Therapeutics MetabolicNeurology Rare NDA Submitted 10
ELTX Elicio Therapeutics Oncology Phase 2 6
ELOX Eloxx Pharmaceuticals Renal Rare Phase 2 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 Phase 3 6
ERAS Erasca Oncology Phase 1 4
ETON Eton Pharmaceuticals GI/HepatologyMetabolic+1 Rare Approved 14
EVMN Evommune DermatologyImmunology+1 Phase 2 6
EXEL Exelixis CardiovascularOncology Approved 21
EYPT EyePoint Ophthalmology Phase 3 3
FHTX Foghorn Therapeutics Oncology Phase 1 1
FBRX Forte Biosciences DermatologyGI/Hepatology Phase 2 3
FBIO Fortress Biotech DermatologyHematology+1 Rare Approved 12
GUTS Fractyl Health Metabolic Phase 3 3
GANX Gain Therapeutics MetabolicNeurology Rare Phase 2 5
GHRS GH Research NeurologyWomen's Health Phase 2 4
GOSS Gossamer Bio Cardiovascular Rare Phase 3 4
GRCE Grace Therapeutics Neurology Rare NDA Submitted 3
GLSI Greenwich LifeSciences Oncology Phase 3 1
IMTX Immatics Oncology Phase 2 8
IMMX Immix Biopharma Hematology Rare Phase 2 1
IMRX Immuneering Oncology Phase 3 5
IMUX Immunic GI/HepatologyNeurology Phase 3 4
IBRX ImmunityBio Infectious DiseaseOncology NDA Submitted 16
IMNM Immunome Oncology NDA Submitted 9
IMVT Immunovant ImmunologyNeurology Rare Phase 2 6
INAB IN8bio ImmunologyOncology Phase 2 6
IXHL Incannex Healthcare ImmunologyNeurology+1 Phase 2 3
NTLA Intellia Therapeutics CardiovascularImmunology Rare NDA Submitted 5
JBIO Jade Biosciences ImmunologyRenal Rare Phase 2 6
JANX Janux Therapeutics Oncology Phase 1 2
KPRX Kiora Pharmaceuticals Ophthalmology Rare Phase 2 5
KOD Kodiak Sciences Ophthalmology Phase 3 7
KURA Kura Oncology MetabolicOncology Approved 9
KYMR Kymera Therapeutics DermatologyRespiratory Rare Phase 2 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare NDA Submitted 7
LRMR Larimar Therapeutics Neurology Rare NDA Submitted 1
LXEO Lexeo Therapeutics CardiovascularNeurology Rare Phase 1 8
LGVN Longeveron CardiovascularMetabolic+1 Rare Phase 2 4
MAIA MAIA Biotechnology Oncology Phase 3 7
MRKR Marker Therapeutics Oncology Phase 1 4
MDNAF Medicenna Therapeutics Oncology Phase 3 9
MIST Milestone Pharmaceuticals Cardiovascular Phase 3 3
INKT MiNK Therapeutics ImmunologyOncology+1 Rare Phase 2 7
GLUE Monte Rosa Therapeutics CardiovascularDermatology+2 Rare Phase 1 8
NKTR Nektar Therapeutics DermatologyImmunology+2 Phase 2 11
NGEN NervGen Pharma Neurology Phase 1 4
NGNE Neurogene Neurology Rare Phase 3 1
NKTX Nkarta ImmunologyNeurology+1 Rare Phase 1 7
NBP NovaBridge Biosciences OncologyOphthalmology Phase 2 6
NRXP NRX Pharmaceuticals Neurology NDA Submitted 5
NRIX Nurix Therapeutics ImmunologyNeurology+1 Phase 2 15
NVCT Nuvectis Pharma Oncology Phase 1 3
OCGN Ocugen Infectious DiseaseOphthalmology Rare Phase 3 13
OCS Oculis Holding NeurologyOphthalmology Phase 3 5
OMER Omeros HematologyNeurology+2 Rare NDA Submitted 7
IRD Opus Genetics Ophthalmology Rare Approved 12
ORKA Oruka Therapeutics DermatologyImmunology Rare Phase 2 6
OTLK Outlook Therapeutics Ophthalmology NDA Submitted 3
OVID Ovid Therapeutics Neurology Rare Phase 1 6
KTTA Pasithea Therapeutics NeurologyOncology Rare Phase 1 4
PEPG PepGen Neurology Rare Phase 2 1
CATX Perspective Therapeutics Oncology Phase 1 4
PHIO Phio Pharmaceuticals Oncology Phase 1 4
PMVP PMV Pharmaceuticals Oncology Phase 2 7
PCSA Processa Pharmaceuticals GI/HepatologyOncology+1 Rare Phase 2 7
PMN ProMIS Neurosciences Neurology Rare Phase 1 6
TARA Protara Therapeutics DermatologyMetabolic+1 Rare Phase 3 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare Phase 2 8
RLMD Relmada Therapeutics MetabolicOncology Rare Phase 2 4
REPL Replimune Group Oncology NDA Submitted 5
RVPH Reviva Pharmaceuticals CardiovascularDermatology+2 Rare Phase 3 10
RYTM Rhythm Pharmaceuticals Metabolic Rare Approved 13
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare Approved 4
SGMT Sagimet Biosciences DermatologyMetabolic Phase 3 5
SANA Sana Biotechnology MetabolicOncology Phase 1 5
SRPT Sarepta Therapeutics Neurology Rare Approved 10
SCYX Scynexis Infectious Disease Approved 4
SLS SELLAS Life Sciences Group Oncology Phase 3 8
SLDB Solid Biosciences CardiovascularNeurology Rare Phase 3 6
SPRB Spruce Biosciences Metabolic Rare Preclinical 2
SYRE Spyre Therapeutics Immunology Phase 2 12
GPCR Structure Therapeutics MetabolicRespiratory Rare Phase 2 5
SMMT Summit Therapeutics Oncology Phase 3 3
STRO Sutro Biopharma Oncology Phase 1 4
TNGX Tango Therapeutics Oncology Phase 1 6
TSHA Taysha Gene Therapies Neurology Rare Phase 3 4
TECX Tectonic Therapeutic Cardiovascular Rare Phase 2 3
TENX Tenax Therapeutics Cardiovascular Rare Phase 3 2
TGTX Tg Therapeutics Neurology Rare Approved 4
TVTX Travere Therapeutics MetabolicRenal Rare Approved 7
TTRX Turn Therapeutics DermatologyInfectious Disease Phase 3 4
TYRA Tyra Biosciences MetabolicOncology Rare Phase 2 5
RARE Ultragenyx Pharmaceutical CardiovascularGI/Hepatology+2 Rare Approved 12
UNCY Unicycive Therapeutics Renal NDA Submitted 2
QURE uniQure HematologyMetabolic+1 Rare Approved 6
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare Approved 26
VERA Vera Therapeutics Infectious DiseaseRenal Rare Approved 8
VKTX Viking Therapeutics GI/HepatologyMetabolic+1 Rare Phase 3 9
VIR Vir Biotechnology Infectious DiseaseOncology Rare Phase 3 10
VRDN Viridian Therapeutics Ophthalmology Approved 6
VOR Vor Biopharma ImmunologyNeurology Rare Phase 3 4
VYGR Voyager Therapeutics MetabolicNeurology Rare Phase 1 7
VTVT vTv Therapeutics MetabolicRespiratory Rare Phase 3 8
WVE Wave Life Sciences MetabolicNeurology+1 Rare Phase 2 5
XNCR Xencor HematologyImmunology+4 Rare Approved 30
XENE Xenon Pharmaceuticals Neurology Phase 3 6
ZBIO Zenas BioPharma DermatologyImmunology+1 Rare NDA Submitted 11
ZURA Zura Bio DermatologyImmunology Rare Phase 2 4
ZYME Zymeworks OncologyRespiratory Approved 11